Is Skye Bioscience, Stock a Good Investment?
Skye Bioscience, Investment Advice | SKYE |
- Examine Skye Bioscience,'s financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Skye Bioscience,'s leadership team and their track record. Good management can help Skye Bioscience, navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact Skye Bioscience,'s business and its evolving consumer preferences.
- Compare Skye Bioscience,'s performance and market position to its competitors. Analyze how Skye Bioscience, is positioned in terms of product offerings, innovation, and market share.
- Check if Skye Bioscience, pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Skye Bioscience,'s stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Skye Bioscience, Common stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Skye Bioscience, Common is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Over hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Moves indifferently to market moves | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Skye Bioscience, Stock
Researching Skye Bioscience,'s stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 85.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.05. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Skye Bioscience, Common recorded a loss per share of 3.6. The entity had not issued any dividends in recent years. The firm had 1:250 split on the 8th of September 2023.
To determine if Skye Bioscience, is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Skye Bioscience,'s research are outlined below:
| Skye Bioscience, generated a negative expected return over the last 90 days | |
| Skye Bioscience, has high historical volatility and very poor performance | |
| Skye Bioscience, Common currently holds 4.62 M in liabilities with Debt to Equity (D/E) ratio of 0.84, which is about average as compared to similar companies. Skye Bioscience, Common has a current ratio of 0.89, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Skye Bioscience,'s use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (37.64 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Skye Bioscience, Common currently holds about 2.93 M in cash with (13.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01. | |
| Skye Bioscience, has a frail financial position based on the latest SEC disclosures | |
| Over 85.0% of Skye Bioscience, shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Skye Bioscience to Present at J.P. Morgan Healthcare Conference |
Earnings surprises can significantly impact Skye Bioscience,'s stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Skye Bioscience,'s investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2016-05-13 | 2016-03-31 | -0.07 | -0.06 | 0.01 | 14 | ||
2024-05-10 | 2024-03-31 | -0.16 | -0.18 | -0.02 | 12 | ||
2024-11-07 | 2024-09-30 | -0.25 | -0.1 | 0.15 | 60 | ||
2024-03-22 | 2023-12-31 | -0.38 | -0.63 | -0.25 | 65 |
Skye Bioscience,'s market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 163.52 M.Market Cap |
|
Skye Bioscience,'s profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.15) | (3.31) | |
| Return On Capital Employed | 6.97 | 3.58 | |
| Return On Assets | (3.15) | (3.31) | |
| Return On Equity | 17.66 | 18.54 |
Determining Skye Bioscience,'s profitability involves analyzing its financial statements and using various financial metrics to determine if Skye Bioscience, is a good buy. For example, gross profit margin measures Skye Bioscience,'s profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Skye Bioscience,'s profitability and make more informed investment decisions.
Please note, the presentation of Skye Bioscience,'s financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Skye Bioscience,'s management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Skye Bioscience,'s management manipulating its earnings.
Evaluate Skye Bioscience,'s management efficiency
Skye Bioscience, Common has return on total asset (ROA) of (0.3039) % which means that it has lost $0.3039 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5482) %, meaning that it created substantial loss on money invested by shareholders. Skye Bioscience,'s management efficiency ratios could be used to measure how well Skye Bioscience, manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Equity is expected to grow to 18.54, whereas Return On Tangible Assets are forecasted to decline to (3.31). At present, Skye Bioscience,'s Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 12.2 M, whereas Total Assets are forecasted to decline to about 6 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.30) | (0.32) | |
| Tangible Book Value Per Share | (0.30) | (0.32) | |
| Enterprise Value Over EBITDA | (1.65) | (1.57) | |
| Price Book Value Ratio | (8.94) | (8.49) | |
| Enterprise Value Multiple | (1.65) | (1.57) | |
| Price Fair Value | (8.94) | (8.49) | |
| Enterprise Value | 20.2 M | 11.7 M |
The strategic vision of Skye Bioscience, Common management plays a critical role in its financial performance. By evaluating this vision, we provide insights into the stock's growth potential.
Beta 1.75 |
Basic technical analysis of Skye Stock
As of the 24th of December, Skye Bioscience, has the Risk Adjusted Performance of (0.07), coefficient of variation of (1,025), and Variance of 56.75. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Skye Bioscience, Common, as well as the relationship between them. Please validate Skye Bioscience, Common market risk adjusted performance, information ratio, as well as the relationship between the Information Ratio and skewness to decide if Skye Bioscience, is priced more or less accurately, providing market reflects its prevalent price of 2.7 per share. Please also confirm Skye Bioscience, Common jensen alpha, which is currently at (0.74) to double-check the company can sustain itself at a future point.Skye Bioscience,'s insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Skye Bioscience, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Skye Bioscience,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Skye Bioscience, insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Schwab Andrew J. over two weeks ago Insider Trading | ||
Grayson Paul A. over a month ago Disposition of 307 shares by Grayson Paul A. of Skye Bioscience, at 5.55 subject to Rule 16b-3 | ||
Dhillon Punit over a month ago Acquisition by Dhillon Punit of 110000 shares of Skye Bioscience, at 0.0171 subject to Rule 16b-3 | ||
Jenkins Annalisa over a month ago Acquisition by Jenkins Annalisa of 70000 shares of Skye Bioscience, at 5.15 subject to Rule 16b-3 | ||
5am Partners Vii, Llc over three months ago Disposition of tradable shares by 5am Partners Vii, Llc of Skye Bioscience, at 6.06 subject to Rule 16b-3 | ||
5am Partners Vii, Llc over three months ago Disposition of 1440 shares by 5am Partners Vii, Llc of Skye Bioscience, at 6.6 subject to Rule 16b-3 |
Skye Bioscience,'s Outstanding Corporate Bonds
Skye Bioscience, issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Skye Bioscience, Common uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Skye bonds can be classified according to their maturity, which is the date when Skye Bioscience, Common has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MPLX LP 4875 Corp BondUS55336VAG59 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| SWKS 3 01 JUN 31 Corp BondUS83088MAL63 | View | |
| SWKS 18 01 JUN 26 Corp BondUS83088MAK80 | View | |
| US830867AB33 Corp BondUS830867AB33 | View |
Understand Skye Bioscience,'s technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Skye Bioscience,'s various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 4.06 | |||
| Mean Deviation | 4.74 | |||
| Coefficient Of Variation | (1,025) | |||
| Standard Deviation | 7.53 | |||
| Variance | 56.75 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | 4.05 | |||
| Maximum Drawdown | 42.81 | |||
| Value At Risk | (7.88) | |||
| Potential Upside | 9.46 | |||
| Skewness | (2.46) | |||
| Kurtosis | 14.37 |
| Risk Adjusted Performance | (0.07) | |||
| Market Risk Adjusted Performance | 4.06 | |||
| Mean Deviation | 4.74 | |||
| Coefficient Of Variation | (1,025) | |||
| Standard Deviation | 7.53 | |||
| Variance | 56.75 | |||
| Information Ratio | (0.10) | |||
| Jensen Alpha | (0.74) | |||
| Total Risk Alpha | (0.97) | |||
| Treynor Ratio | 4.05 | |||
| Maximum Drawdown | 42.81 | |||
| Value At Risk | (7.88) | |||
| Potential Upside | 9.46 | |||
| Skewness | (2.46) | |||
| Kurtosis | 14.37 |
Consider Skye Bioscience,'s intraday indicators
Skye Bioscience, intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Skye Bioscience, stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Skye Bioscience, Corporate Filings
| 19th of December 2024 Other Reports | ViewVerify | |
F4 | 20th of November 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
8K | 7th of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Skye Stock media impact
Far too much social signal, news, headlines, and media speculation about Skye Bioscience, that are available to investors today. That information is available publicly through Skye media outlets and privately through word of mouth or via Skye internal channels. However, regardless of the origin, that massive amount of Skye data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Skye Bioscience, news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Skye Bioscience, relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Skye Bioscience,'s headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Skye Bioscience, alpha.
Skye Bioscience, Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Skye Bioscience, can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Skye Bioscience, Corporate Management
| BA BA | President, Chairman | Profile | |
| Kaitlyn CPA | Chief Officer | Profile | |
| FACE MD | Chief Officer | Profile | |
| Tu MSc | Chief Officer | Profile | |
| Christopher Twitty | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Skye Bioscience, Common. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.60) | Return On Assets (0.30) | Return On Equity (0.55) |
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Skye Bioscience,'s value and its price, as these two are different measures arrived at by various means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.